B VAISSE CHU TIMONE MARSEILLE Que deviennent les btabloquants
dans lHTA aujourd'hui ?
Page 2
LES BTABLOQUANTS DANS LHTA : les Mta Analyses
Page 3
Effet de la baisse de PA sur les vnements cardiovasculaires
majeurs Mtanalyse des Blood Pressure Lowering Treatment Trialists
THE LANCET Vol 362 November 8, 2003
Page 4
Should blockers remain first choice in the treatment of primary
hypertension? A meta-analysis Beta Blockers versus Other Drugs
Lindholm Lancet 2005; 366: 154553
Page 5
EVALUATION DE LEFFICACITE DES BETA BLOQUANTS DANS LHTA : SUJETS
< 60 ANS Khan Mc Alister CMAJ 2006;174(12):1737-42 Mortalit,
AVC, IDM
Page 6
EVALUATION DE LEFFICACITE DES BETA BLOQUANTS DANS LHTA : SUJETS
> 60 ANS Khan Mc Alister CMAJ 2006;174(12):1737-42 Mortalit,
AVC, IDM
Page 7
Page 8
Relative risk estimates of coronary heart disease events and
stroke in single drug blood pressure difference trials according to
class of drug M R Law BMJ 2009;338;b1665
Page 9
Relative risk estimates of coronary heart disease events in
single drug blood pressure difference trials according to drug (
blockers or other), presence of CHD, and for blockers according to
acute myocardial infarction on entry. M R Law BMJ
2009;338;b1665
Page 10
Relative risk estimates of coronary heart disease events and
stroke in 46 drug comparison trials comparing each of the five
classes of blood pressure lowering drug with any other class of
drug M R Law BMJ 2009;338;b1665
Page 11
LES BTABLOQUANTS DANS LHTA : les Grandes Etudes
Page 12
0 2 4 6 8 10 12 14 16 Proportion of patients with first event
(%) Intention-to-Treat Losartan Atenolol LIFE: Primary Composite
Endpoint Study Month0612182430364248546066 Losartan
(n)46054524446043924312424741894112404738971889901 Atenolol
(n)45884494441443494289420541354066399238211854876 Adjusted Risk
Reduction 130%, p=0021 Unadjusted Risk Reduction 146%, p=0009 B
Dahlof et al. Lancet 2002;359:995-1003
Page 13
LIFE : prvention des AVC en fonction de lge Kizer ;
Hypertension. 2005;45:46-52